UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2022, 2026

TOTALIGENT, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41803

80-0142655

(State or other

jurisdiction of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3651 FAU Boulevard, Suite 400

Boca Raton, Florida

33431

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (561) 360-3565

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12b of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange Registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On March 422, 2026, Totaligent, Inc. (the “Company”) entered into an Extension Amendment (the “Amendment”) to the Binding Letter of Intent dated February 1122, 2026 (the “LOI”) with ~~Aetherium~~GloMed ~~Medical~~Solutions Limited Liability Company (“~~Aetherium~~GloMed”). As previously disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 1223, 2026, the LOI sets forth the principal terms for a proposed ~~acqui-hire~~ transaction pursuant to which the Company and GloMed would ~~acquire~~form ~~Aetherium’s~~a ~~team,~~joint ~~business~~venture ~~plan,~~and ~~intellectual~~the ~~property,~~Company ~~know-how,~~would ~~contacts,~~receive ~~and~~a ~~related~~call ~~assets~~option into ~~exchange~~acquire ~~for~~GloMed, ~~equity~~including inits ~~the~~business ~~Company~~operations, intellectual property, and related assets.

The Amendment extends the target date for the negotiation and execution of definitive agreements (including, but not limited to, joint venture agreements, asset contribution agreements, intellectual property assignment agreements, ~~employment or consulting agreements,~~ and ~~restricted~~related ~~stock~~transaction ~~agreements~~documents), and the target closing date of the transaction, ~~from March 5, 2026,~~ to April 1022, 2026, to allow additional time for completion of negotiations and due diligence. The binding exclusivity period set forth in the LOI has been extended through April 1022, 2026, or such earlier date as provided in the LOI, and is not affected by the Amendment. Except as expressly amended, all terms and conditions of the LOI remain in full force and effect.

The foregoing description is qualified in its entirety by reference to the Amendment, a copy of which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Extension Amendment to Binding Letter of Intent, dated March 2022, 2026, between Totaligent, Inc. and ~~Aetherium~~GloMed ~~Medical~~Solutions Limited Liability Company.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	TOTALIGENT, INC.
Date: March 24, 2026	By:	/s/ Edward C. DeFeudis
Date: March 26, 2026	By:	/s/ EDWARD C DEFEUDIS
		Edward C. DeFeudis
		Edward C. DeFeudis CEO
		CEO

Filing Compare · Totaligent, Inc.